

Antibody	Mechanism of action	Clinical trial type	Targeted disease	Way of administration	Date of completion	Participants	Aim	Results / Status	NCT id
AL002	TREM2 agonist	Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose escalation study	AD	IV	November 2020	69 participants: healthy volunteers (18-85 years) and mild to moderate AD (50-85 years)	To assess safety, immunogenicity, tolerability, pharmacokinetics, and pharmacodynamics of AL002	AL002 is safe and well tolerated by healthy volunteers and AD patients	NCT03635047
AL002	TREM2 agonist	Phase 2, randomized, double-blind, placebo-controlled study	AD	IV	January 2024	265 participants (estimated): early AD (MMSE > 22)	To evaluate efficacy and safety of AL002 in participants with Early Alzheimer's Disease.	Recruiting	NCT04592874
DNL919	TREM2 agonist	Phase 1, randomized, placebo-controlled, double-blind, single ascending dose study	AD	IV	July 2023	80 participants (estimated): healthy volunteers (18 - 55 years)	To evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL919.	Recruiting	NCT05450549